What was the market valuation of the US pharmaceutical contract-manufacturing market in 2024?

The market valuation was $52.74 Billion in 2024. Read More

What is the projected market valuation for the US pharmaceutical contract-manufacturing market by 2035?

The projected valuation for 2035 is $86.16 Billion. Read More

Which companies are considered key players in the US pharmaceutical contract-manufacturing market?

Key players include Lonza Group, Catalent, Samsung Biologics, Boehringer Ingelheim, and others. Read More

What are the main segments of the US pharmaceutical contract-manufacturing market?

Main segments include Manufacturing Type, Service Type, Therapeutic Area, and End User. Read More

What was the valuation of Active Pharmaceutical Ingredients in 2024?

The valuation for Active Pharmaceutical Ingredients was $15.0 Billion in 2024. Read More

How much is the Formulated Products segment projected to grow by 2035?

The Formulated Products segment is projected to grow to $40.0 Billion by 2035. Read More

What is the projected valuation for Contract Research services by 2035?

The projected valuation for Contract Research services is $25.0 Billion by 2035. Read More

Which therapeutic area had the highest valuation in 2024?

Oncology had the highest valuation at $15.0 Billion in 2024. Read More

What is the projected market size for Pharmaceutical Companies as end users by 2035?

The projected market size for Pharmaceutical Companies as end users is $48.0 Billion by 2035. Read More

US Pharmaceutical Contract Manufacturing Market

Q: What is the expected CAGR for the US pharmaceutical contract-manufacturing market during the forecast period 2025 - 2035?

The expected CAGR during this period is 4.56%. Read More

ID: MRFR/HS/13111-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

United States Pharmaceutical Contract Manufacturing Market Research Report: Size, Share, Trend Analysis - Growth Outlook & Industry Forecast 2025 To 2035

US Pharmaceutical Contract Manufacturing Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Manufacturing Type (USD Billion)
  1. 4.1.1 Active Pharmaceutical Ingredients
  2. 4.1.2 Formulated Products
  3. 4.1.3 Packaging Services
2. 4.2 Pharmaceutical, BY Service Type (USD Billion)
  1. 4.2.1 Contract Manufacturing
  2. 4.2.2 Contract Research
  3. 4.2.3 Product Development
3. 4.3 Pharmaceutical, BY Therapeutic Area (USD Billion)
  1. 4.3.1 Oncology
  2. 4.3.2 Cardiology
  3. 4.3.3 Neurology
  4. 4.3.4 Infectious Diseases
4. 4.4 Pharmaceutical, BY End User (USD Billion)
  1. 4.4.1 Pharmaceutical Companies
  2. 4.4.2 Biotechnology Companies
  3. 4.4.3 Generic Drug Manufacturers
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Lonza Group (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Catalent (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Samsung Biologics (KR)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Boehringer Ingelheim (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Fujifilm Diosynth Biotechnologies (JP)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Recipharm (SE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 WuXi AppTec (CN)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Aenova Group (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Patheon (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY MANUFACTURING TYPE
3. 6.3 US MARKET ANALYSIS BY SERVICE TYPE
4. 6.4 US MARKET ANALYSIS BY THERAPEUTIC AREA
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY MANUFACTURING TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY MANUFACTURING TYPE, 2024 TO 2035 (USD Billion)
14. 6.14 PHARMACEUTICAL, BY SERVICE TYPE, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY SERVICE TYPE, 2024 TO 2035 (USD Billion)
16. 6.16 PHARMACEUTICAL, BY THERAPEUTIC AREA, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
18. 6.18 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY MANUFACTURING TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY SERVICE TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Pharmaceutical Market Segmentation

Pharmaceutical By Manufacturing Type (USD Billion, 2025-2035)

Active Pharmaceutical Ingredients
Formulated Products
Packaging Services

Pharmaceutical By Service Type (USD Billion, 2025-2035)

Contract Manufacturing
Contract Research
Product Development

Pharmaceutical By Therapeutic Area (USD Billion, 2025-2035)

Oncology
Cardiology
Neurology
Infectious Diseases

Pharmaceutical By End User (USD Billion, 2025-2035)

Pharmaceutical Companies
Biotechnology Companies
Generic Drug Manufacturers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”